JSPR

Jasper Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.60
52-Week Range: $0.32 – $2.69
Market Cap: $18.81M
P/E (TTM): —
EPS (TTM): -0.93
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 11.30
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: —
Debt/Equity: —
Total Debt: —
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: —

JSPR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$34.63M	$51.78M	$55.82M	$63.10M
Selling, General & Admin	$16.57M	$17.08M	$20.42M	$20.78M
Operating Expenses	$51.20M	$68.86M	$76.24M	$83.88M
Operating Income	-$51.20M	-$68.86M	-$76.24M	-$83.88M
EBITDA	-$50.22M	-$67.75M	-$74.87M	-$82.83M
Pretax Income	-$37.69M	-$64.47M	-$71.27M	-$75.80M
Net Income	-$37.69M	-$64.47M	-$71.27M	-$75.80M
Diluted EPS	-10.30	-6.18	-4.89	-3.95
Diluted Shares	3.65M	10.44M	14.58M	19.17M

JSPR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$38.25M	$86.89M	$71.64M	$28.69M
Receivables	$913.00K	$250.00K	$0.00	—
Current Assets	$41.73M	$88.94M	$75.81M	$34.65M
Total Assets	$48.36M	$94.89M	$79.90M	$35.78M
Current Liabilities	$7.07M	$12.37M	$15.24M	$13.20M
Total Debt	$3.65M	$2.79M	$1.81M	$1.24M
Total Liabilities	$12.37M	$16.45M	$18.23M	$31.63M
Retained Earnings	-$105.14M	-$169.60M	-$240.87M	-$316.67M
Shareholders' Equity	$35.99M	$78.44M	$61.67M	$4.15M
Working Capital	$34.67M	$76.56M	$60.57M	$21.45M

JSPR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$45.86M	-$52.07M	-$62.60M	-$77.16M
Capital Expenditure	-$576.00K	-$267.00K	-$552.00K	-$7.00K
Free Cash Flow	-$46.43M	-$52.33M	-$63.15M	-$77.17M
Depreciation & Amortisation	$975.00K	$1.11M	$1.37M	$1.06M
Stock-Based Compensation	$4.09M	$5.21M	$6.62M	$6.71M
Investing Cash Flow	-$576.00K	-$267.00K	-$532.00K	$5.00K
Financing Cash Flow	$55.00K	$100.97M	$47.88M	$34.21M
Net Change in Cash	-$46.38M	$48.64M	-$15.25M	-$42.95M

JSPR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.16M	$21.20M	$14.39M	$11.36M	$5.81M	$5.13M
Selling, General & Admin	$5.64M	$5.88M	$4.78M	$4.48M	$5.14M	$4.07M
Operating Expenses	$21.80M	$27.08M	$19.17M	$15.84M	$10.95M	$9.21M
Operating Income	-$21.80M	-$27.08M	-$19.17M	-$15.84M	-$10.95M	-$9.21M
EBITDA	-$21.52M	-$26.82M	-$18.94M	-$15.55M	-$10.93M	-$9.19M
Pretax Income	-$21.24M	-$26.72M	-$18.74M	-$9.10M	-$1.17M	-$2.76M
Net Income	-$21.24M	-$26.72M	-$18.74M	-$9.10M	-$1.17M	-$2.76M
Diluted EPS	-1.41	-1.74	-1.13	-0.32	-0.04	-0.10
Diluted Shares	15.02M	15.33M	16.64M	28.66M	28.67M	28.70M

JSPR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$48.80M	$39.51M	$50.90M	$28.69M	$14.14M	$7.31M
Current Assets	$53.17M	$42.97M	$54.56M	$34.65M	$20.29M	$11.57M
Total Assets	$57.60M	$46.47M	$57.47M	$35.78M	$21.18M	$11.80M
Current Liabilities	$12.33M	$20.50M	$21.04M	$13.20M	$9.00M	$7.84M
Total Debt	$2.59M	$2.15M	$1.70M	$1.24M	$757.00K	$270.00K
Total Liabilities	$15.35M	$22.96M	$45.90M	$31.63M	$17.78M	$10.39M
Retained Earnings	-$262.11M	-$288.83M	-$307.57M	-$316.67M	-$317.84M	-$320.60M
Shareholders' Equity	$42.24M	$23.50M	$11.57M	$4.15M	$3.40M	$1.41M
Working Capital	$40.84M	$22.47M	$33.52M	$21.45M	$11.30M	$3.73M

JSPR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$22.84M	-$15.45M	-$17.00M	-$21.87M	-$14.55M	-$6.92M
Free Cash Flow	-$22.84M	-$15.46M	-$17.00M	-$21.87M	-$14.55M	-$6.92M
Depreciation & Amortisation	$279.00K	$258.00K	$229.00K	$290.00K	$21.00K	$21.00K
Stock-Based Compensation	$1.81M	$1.82M	$1.42M	$1.66M	$423.00K	$764.00K
Investing Cash Flow	$4.00K	$1.00K	$0.00	$0.00	$0.00	$80.00K
Financing Cash Flow	$0.00	$6.16M	$28.39M	-$340.00K	—	—
Net Change in Cash	-$22.84M	-$9.29M	$11.39M	-$22.21M	-$14.55M	-$6.83M

Market Snapshot

About

Jasper Therapeutics is a clinical-stage biotechnology company developing therapies based on targeting CD117 (c-Kit) for hematopoietic stem cell transplant conditioning and cancer treatment. The company's lead product candidate is briquilimab, an antibody designed to clear hematopoietic stem cells from bone marrow to prepare patients for transplantation without the need for toxic chemotherapy or radiation. Jasper's approach aims to make stem cell transplants safer and accessible to more patients, potentially transforming treatment for blood disorders, autoimmune diseases, and cancer. The company is advancing multiple clinical trials evaluating briquilimab in various conditioning applications.